Omnium Return

Omnium Return delivers a more complete view of the commercial potential of assets, covering all phases of clinical development. With 8 times more coverage than consensus models, it provides a credible and comprehensive assessment of product potential that is 21% more accurate in predicting the commercial return of Phase I assets.*

_{*When compared to calculations based on industry average benchmarks.}

An independent and balanced view of asset potential that leverages machine learning to provide systematic, comprehensive coverage across of all phases of the clinical pipeline, while more accurately predicting the value of R&D assets:

• USA peak sales predictions for all products and indications in development
• Extrapolation of USA sales to Rest of World – giving a global view
• Indication benchmarks to put peak predictions in market context

Provides time-to-peak analysis that enables better assessment of market impact and helps inform product launch planning:

• USA time to peak benchmarks by indication
• Market exclusivity impact and expiry
• Time-to-peak values for historically launched products

Key pricing data to streamline research and inform pricing strategies, including consolidated USA pack pricing for approved products, current cost-per-patient values for launched products and benchmarks for annual cost-per-patient by indication and technology.

Unique data that identifies the current market access position for products launched in the USA, with benchmarks that help assess the implications and opportunities for products in development.

Quantifies and standardises the degree of unmet need within an indication, so you can rank or compare indications to better focus portfolio investments on areas with the greatest impact to patients.